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50% persist, primarily because of neointimal hyperpla-
sia and subsequent accelerated atherosclerosis.1-3 These
vein graft failures result in significant morbidity and
mortality and represent a major limitation in the long-
term treatment of ischemic arterial disease.
Whereas inhibition of human neointimal hyperplasia
has eluded traditional pharmacologic approaches,4 a
growing understanding of the molecular biology of vas-
cular cell activation and proliferation has allowed the
design of interventions at the level of gene expression
that have successfully altered the course of experimen-
tal vein graft disease.5,6 We have previously reported
that blockade of cell-cycle regulatory genes through
intraoperative transfection of a combination of anti-
sense oligodeoxynucleotides (ODNs) inhibited neointi-
A lthough autologous vein remains the most com-monly used conduit for coronary and peripheral
bypass grafting, vein graft occlusion rates of 30% to
Objective: We tested the hypothesis that a single intraoperative transfection
of rabbit vein grafts with a decoy oligonucleotide that blocks cell-cycle gene
transactivation by the transcription factor E2F induces long-term stable
adaptation that involves medial hypertrophy and a resistance to neointimal
hyperplasia and atherosclerosis.
Methods: Jugular vein to carotid artery interposition vein grafts in hyperc-
holesterolemic rabbits were treated, using pressure-mediated delivery, with
either E2F decoy oligonucleotide, scrambled oligonucleotide, or vehicle
alone. E2F decoy inhibition of cell-cycle gene expression was determined
by measuring proliferating cell nuclear antigen upregulation and bromode-
oxyuridine incorporation in vascular smooth muscle cells. Neointimal
hyperplasia and atherosclerosis were compared between groups at 6
months after operation. Wall stress was derived from the ratio of luminal
radius to wall thickness. Normal rabbits exposed to 6 weeks of diet-
induced hypercholesterolemia starting 6 months after operation were ana-
lyzed in the same manner.
Results: The E2F decoy oligonucleotide, but not scrambled oligonucleotide
or vehicle alone, inhibited proliferating cell nuclear antigen expression and
smooth muscle cell proliferation. Furthermore, this manipulation of cell-
cycle gene expression yielded an inhibition of neointimal hyperplasia and
atherosclerotic plaque formation throughout the 6 months of cholesterol
feeding. In normocholesterolemic rabbits, vehicle-treated and scrambled
oligonucleotide-treated vein grafts remain susceptible to diet-induced ather-
osclerosis as well, whereas resistance to this disease induction remained sta-
ble in genetically engineered grafts.
Conclusion: A single intraoperative pressure-mediated delivery of E2F decoy
effectively provides vein grafts with long-term resistance to neointimal
hyperplasia and atherosclerosis. These findings suggest that long-term
reduction in human vein graft failure rates may be feasible with this ex vivo
gene therapy approach. (J Thorac Cardiovasc Surg 2001;121:714-22)
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mal hyperplasia in rabbit vein grafts for up to 10 weeks
after implantation.7 Adaptive wall thickening and
reduction of wall stress was instead achieved through
hypertrophy of the medial layer, and, together with a
stabilization of endothelial function, this alteration in
graft wall architecture prevented the development of
accelerated diet-induced atherosclerosis.
The E2F-1 transcription factor is released from a reg-
ulatory complex involving the retinoblastoma gene
product on the latter’s hyperphosphorylation at a criti-
cal juncture in the late G1 phase of the cell cycle.8 Free
E2F has been associated with the upregulated expres-
sion of a dozen genes involved in subsequent DNA syn-
thesis and cell-cycle progression (Fig 1).9-11 Our labo-
ratory has previously documented that blockade of this
transcription factor with a double-stranded decoy ODN
bearing the consensus E2F-binding site inhibits the
upregulation of multiple cell-cycle genes in vascular
cells in a sequence-specific and coordinated fashion.12
In this study we tested the hypothesis that single-
agent genetic treatment of vein grafts with E2F decoy
ODNs not only redirects graft biology away from
neointimal hyperplasia and toward medial hypertrophy
as an adaptive response to arterial hemodynamics but
also provides a stabilization of the graft wall that
endows the vessel with long-term resistance to neointi-
mal and atherosclerotic disease. This genetic manipula-
tion was achieved ex vivo by using a nondistending
pressure-mediated delivery system13 without the use of
liposomes or viral vectors and may therefore represent
a particularly safe approach toward the genetic engi-
neering of human bypass grafts.
Materials and methods
Oligonucleotides. The double-stranded E2F decoy phos-
phorothioate ODN was custom synthesized (Keystone-
Biosource, Menlo Park, Calif) with the sequence 5´-CTA-
GATTTCCCGCG-3´, which contains the E2F consensus
binding sequence found in the human c-myc promoter. The
scrambled ODN used as a control in this study has the follow-
ing sequence: 5´-TCCAGCTTCGTAGC-3´. ODN was dis-
solved at a concentration of 40 µmol/L in normal saline solu-
tion. Scrambled ODN labeled with fluorescein isothiocyanate
at the 3´ end of one strand was also used for fluorescent micro-
scopic analysis of ODN distribution after transfection.
Vein graft model and ex vivo transfection. New Zealand
white rabbits (3-3.5 kg) were anesthetized with an intra-
venous mixture of ketamine (2.5 mg/mL) and xylazine (0.09
mg/mL). Using the no-touch technique, a 2.5-cm segment of
the right jugular vein was dissected through a midline verti-
cal neck incision, and all branches were carefully ligated with
4-0 silk sutures and divided. Grafts were then cannulated dis-
tally and flushed gently with normal saline solution. The ends
of the cannula and vein were then surrounded by an inelastic
sheath, and ODN solution or vehicle alone was infused
through the lumen of the vessel and into the surrounding
Fig 1. Principle of E2F decoy strategy (TTTCGCGC, consensus sequence for the E2F binding site). A, In a quies-
cent cell state the transcription factor E2F is complexed with retinoblastoma gene product (Rb), cyclin A, and
cyclin-dependent kinase–2 (cdK2). B, Hyperphosphorylation of retinoblastoma gene product releases free E2F,
which binds to enhancer regions of cell-cycle regulatory genes, resulting in their transactivation. C, The E2F decoy
double-stranded ODN binds to free E2F, preventing E2F-mediated transactivation of cell-cycle regulatory genes.
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space. The open end of the sheath was then clamped, and the
fluid surrounding the vein was pressurized to 300 mm Hg.
The graft was incubated under this nondistending pressure
for 20 minutes, at which time the tissue was flushed again
with normal saline solution to remove excess ODN solution.
Animals were heparinized (200 U/kg), the ipsilateral com-
mon carotid artery was clamped distally and proximally, and
the grafts were anastomosed into the divided artery with
interrupted 7-0 polypropylene sutures. All grafts were treated
with 1 to 2 mL of 2% lidocaine solution before wound clo-
sure. Our use of animals in this study was approved by the
Harvard Medical Area Standing Committee on Animals, and
all animal care complied with the “Guide for the Care and
Use of Laboratory Animals,” Institute of Laboratory Animal
Resources, Commission on Life Sciences, National Research
Council (National Academy Press, 1996).
Cholesterol feeding. One group of animals was started on
a 1% cholesterol diet (Dyets, Inc, Bethlehem, Pa) 1 week
before the operation and maintained on that diet until the time
of death. A second group of animals was started on a 1% cho-
lesterol diet 6 months after vein grafting and maintained on
that diet for 6 weeks, at which time the animal was killed.
Serum cholesterol levels in cholesterol-fed animals ranged
from 800 to 2000 mg/dL during the study period (normocho-
lesterolemia being 30-75 mg/dL).
Vessel morphometry. Vein grafts and ungrafted jugular
veins were perfusion fixed at 100 mm Hg and harvested at 6
weeks and 6 months, and paraffin-embedded sections were
stained with hematoxylin–van Geison or with Verhoff–van
Geison stain. Computerized planimetry (model 2200; South
Micro Instruments, Atlanta, Ga) was used to measure the inti-
mal and medial cross-sectional surface areas of each vessel
spaced at 0.75-mm intervals. Neointima was distinguished by
its position relative to the internal elastic lamina and by its
chaotic organization of cells compared with the circumferen-
tial arrangement of medial smooth muscle cells. Luminal
radius and intimal and medial thickness were derived from
these data, and averages for each vessel were calculated. The
ratio of luminal radius to wall thickness is proportional to tan-
gential wall stress by Laplace’s law and was derived as an
indication of tangential wall stress in these vessels.
Bromodeoxyuridine incorporation and immunohisto-
chemistry. An index of cellular proliferation was obtained
through the administration of bromodeoxyuridine (BrdU) at 18
hours (100 mg/kg subcutaneous and 30 mg/kg intravenous) and
12 hours (30 mg/kg intravenous) before harvest. On harvest,
vein grafts are flushed with phosphate-buffered saline solution,
pressure fixed at 100 mm Hg with 10% neutral-buffered forma-
lin for 10 minutes, and snap-frozen in OCT. Immuno-
histochemical staining with a BrdU-labeling kit (Zymed; San
Francisco, Calif) was carried out on 5-µm sections. Eight fields
per section were counted at 400× magnification. The contralat-
eral jugular vein was harvested and analyzed in the same man-
ner as a control vein. Nuclei were counterstained with hema-
toxylin and counted to obtain a labeling index.
Western blot analysis. Whole graft explanted 4 days after
operation was snap-frozen and ground into a powder form
and lysed in an NP-40–based buffer (1% NP-40, 0.5% sodi-
um deoxycholate, and 0.1% sodium dodecylsulfate) contain-
ing protease inhibitors (10 µg/mL phenylmethylsulfonyl 
fluoride and 30 µg/mL aprotinin) and the phosphatase
inhibitor sodium orthovanadate (1 mmol/L; Sigma Chemical
Co, St Louis, Mo). The insoluble fraction was removed by
centrifugation. Proteins were separated in a 10% sodium
dodecyl sulfate–polyacrylamide gel and transferred to a
nitrocellulose membrane (Hybond ECL; Amersham Life
Sciences, Piscataway, NJ). The membrane was incubated
with a polyclonal antibody used for proliferating cell nuclear
antigen (PCNA; Santa Cruz Biotechnology Inc, Santa Cruz,
Calif) for 1 hour and developed by using the ECL system
(Amersham Life Sciences). Computerized image analysis
was used to quantify the relative signal intensities of the
bands using the software NIH Image 1.52 (Bethesda, Md),
and the results were expressed in arbitrary units per micro-
gram of protein.
Statistical analysis. All results are expressed as the mean
± SD. One-way analysis of variance followed by the
Bonferroni multiple comparison test was used to compare
differences between groups.
Results
Inhibition of cell-cycle regulatory elements by
E2F decoy ODN. E2F decoy or scrambled ODN was
delivered to graft vascular smooth muscle cells
(VSMCs) in a highly efficient manner by using
nondistending pressure-mediated transfection, as
previously described.13 Previous reports have docu-
mented a transfection efficiency of approximately
90% of vascular cells in vein grafts with this ex vivo
approach, and this efficiency of transfection was con-
firmed in this study by using fluorescein isothio-
cyanate–labeled ODN (data not shown). Effective
delivery of functional E2F decoy ODN was con-
firmed by means of Western blot analysis for PCNA
in whole graft protein lysates 4 days after treatment
and implantation. We determined that grafts treated
with the E2F decoy ODN had a sequence-specific
inhibition of PCNA upregulation when compared
with vehicle or scrambled ODN-treated grafts (Fig 2,
A and B). Furthermore, grafts harvested 7 days after
implantation, a time when VSMC proliferation is
known to be at its peak, were assessed for BrdU
incorporation in medial cells on 5-mm cross-sec-
tions. These findings once again confirmed that
grafts treated with E2F decoy ODN had an inhibition
of medial VSMC proliferation, as determined by a
significantly lower BrdU-labeling index, when com-
pared with vehicle and scrambled ODN-treated con-
trol grafts (Fig 2, C).
Long-term graft wall stabilization and inhibition
of atherosclerosis. Treatment of grafts with E2F decoy
ODN led to a significant reduction in neointimal thick-
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ness at 6 weeks and 6 months (11 ± 12 and 13 ± 3 µm,
respectively) compared with vehicle-treated (122 ± 12
and 151 ± 12 µm, respectively) or scrambled ODN-
treated (131 ± 9 and 150 ± 10 µm, respectively) grafts.
Instead, the E2F decoy ODN-treated grafts responded
to the increase in hemodynamic stress of the arterial
circulation through a thickening of the medial layer
(Fig 3). The hemodynamic stability achieved by this
medial thickening is reflected in the reduction of wall
stress in E2F decoy ODN-treated grafts to a level sim-
ilar to those seen in the carotid artery and in the control
grafts that underwent significant neointimal hyperpla-
sia (Fig 4).
At 6 months after grafting, extensive plaque was
noted throughout the lengths of all vehicle-treated and
scrambled ODN-treated grafts placed in cholesterol-
fed rabbits. By contrast, the E2F decoy ODN-treated
grafts remained largely free of macroscopic plaque, as
did the ipsilateral grafted and contralateral ungrafted
carotid arteries. Histologic examination of atheroscle-
rotic grafts in control animals revealed lesions rich in
foam cells, many of which were covered by a fibrous
cap of varying cellularity (Fig 5). These complex
lesions were absent in E2F decoy ODN-treated grafts,
in which only occasional foam cells were identified.
Furthermore, the shift in vein graft adaptation seen at
Fig 2. Effect of E2F decoy ODN on PCNA expression and BrdU-labeling index in vein grafts. A, Representative
Western blot demonstrating PCNA protein expression of whole-tissue lysates in ungrafted jugular vein (lane 1) and
in day 4 grafts treated with vehicle (lane 2), E2F decoy ODN (lane 3), or scrambled ODN (lane 4). B, Significant
differences in expression were found between E2F decoy ODN-treated and vehicle-treated or scrambled ODN-
treated grafts (n = 6 for each group, *P < .017). Numbers on the x axis refer to lanes as defined in A. C, E2F decoy
ODN treatment significantly inhibits BrdU incorporation when compared with vehicle-treated or scrambled ODN-
treated groups (n = 3 for each group, *P < .017). VT, Vehicle-treated graft; E2F, E2F decoy ODN-treated graft; Scr,
scrambled ODN-treated graft.
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earlier time points persisted even at 6 months in grafts
that had undergone cell-cycle gene blockade with a sin-
gle E2F decoy ODN transfection at the time of the
operation (Fig 3).
The aggressive development of atherosclerotic
lesions has been well characterized in rabbit vein grafts
that undergo neointimal hyperplasia in the presence of
hypercholesterolemia, whereas plaque formation and
foam cell lesions are not observed, even in long-term
grafts placed in normal rabbits.14,15 Vein graft wall
remodeling stabilizes between 4 and 12 weeks after
implantation, as rates of VSMC proliferation return to
Fig 3. Neointimal, medial, and total wall thickness at 6 weeks and 6 months after placement of vehicle-treated,
scrambled ODN-treated, and E2F decoy ODN-treated vein grafts into cholesterol-fed rabbits. Stable adaptive wall
thickening is achieved in E2F decoy ODN-treated grafts through medial hypertrophy with a minimal degree of
neointimal hyperplasia that does not increase over time (n = 6 for each group; P < .001, intimal thickness of E2F
decoy ODN versus vehicle or scrambled ODN groups at 6 weeks [*] and 6 months [#]).
Fig 4. Tangential wall stress in rabbit carotid artery and vein grafts 6 months after grafting in cholesterol-fed rab-
bits, as reflected by the ratio of lumenal radius to wall thickness. No statistically significant difference was found
between E2F decoy ODN-treated grafts when compared with vehicle or scrambled ODN-treated grafts (n = 6 for
each group).
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low levels and neointimal thickening ceases. We postu-
lated, however, that an increased susceptibility to accel-
erated atherogenesis persists in the hemodynamically
stabilized graft wall that has undergone neointimal
hyperplasia and in which abnormal VSMC and
endothelial cell phenotypes persist and that the alterna-
tive form of graft remodeling achieved after E2F decoy
ODN treatment does not involve this development of
long-term proatherogenic state. Normocholesterolemic
rabbits that had undergone interposition grafting with
vehicle-treated, scrambled ODN-treated, and E2F
decoy ODN-treated veins were then administered a 1%
cholesterol diet for 6 weeks, starting 6 months after the
operation. At the time of harvest, grafts in both control
groups exhibited atherosclerotic lesion formation indis-
tinguishable from 6-week grafts placed in hypercholes-
terolemic rabbits, whereas the gross and microscopic
appearance of E2F decoy ODN-treated grafts reflected
a persistent resistance to this accelerated disease
process (Fig 6). Furthermore, the introduction of ele-
vated cholesterol levels did not induce new neointimal
hyperplasia in E2F decoy ODN-treated grafts (10 ± 3
µm) that had achieved mechanical stabilization through
medial hypertrophy when compared with vehicle-treat-
Fig 5. Light micrographs of scrambled ODN-treated (A and C) and E2F decoy ODN-treated (B and D) vein grafts 6
months after grafting in cholesterol-fed rabbits. Oil red-O staining demonstrates a pronounced, lipid-rich, foam cell
lesion covered by a cap of fibrous tissue in scrambled ODN-treated grafts (C). E2F decoy ODN-treated grafts
remained free of macroscopic plaque and foam cell lesions. Arrows indicate locations of internal elastic laminae
(hematoxylin–van Geison stain: A and B, original magnification 400×).
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ed grafts (138 ± 12 µm) and scrambled ODN-treated
grafts (130 ± 14 µm).
Discussion
In this study we have demonstrated that transfection
of vein grafts with a single ODN designed to block the
activity of the critical cell-cycle regulatory transcription
factor E2F-1 can achieve therapeutic graft wall adapta-
tion without a need for multiple antisense ODNs against
individual cell-cycle genes. In addition, our results indi-
cate that the effect of this alternative approach to cell-
cycle gene inhibition modulates not only patterns of cell
division after operation but phenotype as well because
E2F decoy ODN-treated grafts resisted not only the
development of neointimal hyperplasia but also diet-
induced atherosclerosis. Furthermore, this vein graft
engineering strategy was implemented by using an ex
vivo DNA delivery approach, without exogenous lipid
formulations, viral protein components, live viral prepa-
rations, or other foreign materials that have been used in
previous attempts at modifying vein graft pathogene-
sis5,6,16,17 and therefore represents a particularly safe
means of potentially applying our growing knowledge
of vascular molecular biology to the treatment of human
disease.
Although accelerated in comparison with native arte-
rial atherosclerosis, occlusive vein graft disease is a
progressive process that manifests over the first months
to years after grafting. Although a single delivery of
ODN cannot be expected to remain available to influ-
ence gene expression over this prolonged time course,
we have hypothesized that a pattern of adaptive vascu-
lar remodeling is set during the days after vein grafting
that will lead the vessel either toward or away from the
accelerated disease process. Many forms of vascular
injury have been associated with VSMC activation that
leads to neointima formation. The phenotypic activa-
tion of vascular cells in response to the injuries associ-
ated with surgical trauma, ischemia, initial overdisten-
tion, and perioperative inflammation involves such
proatherosclerotic developments as adhesion molecule
upregulation, cytokine secretion, heightened oxidative
stress, and shifts in endothelium-dependent vasoreac-
tivity.18-21 The neointima, with its phenotypically acti-
vated VSMCs and the leukocytes subsequently attract-
ed by its proinflammatory environment, yields a
substrate for the accelerated atherogenesis seen in
human and experimental vein grafts. In contrast to the
neointimal thickening stimulated by the vascular
injuries associated with vein grafting, arterial models
of hypertension have revealed a mechanism of medial
hypertrophy that allows adaptation to chronically
increased hemodynamic stress without neointimal
layer formation.22,23 This medial hypertrophy involves
both increased protein synthesis and proliferation of
VSMCs in the medial layer that, in the absence of acute
vascular injury, do not take on an activated phenotype
and do not migrate to form a neointimal lesion.
Fig 6. Light micrographs of scrambled ODN-treated (A) and E2F decoy ODN-treated (B) vein grafts in normo-
cholesterolemic rabbits rendered hypercholesterolemic 6 months after grafting. A pronounced fibrous cap is seen
in the scrambled ODN-treated graft, whereas the E2F decoy ODN-treated graft remains free of macroscopic
plaque. Arrows indicate locations of internal elastic laminae (hematoxylin–van Geison stain: original magnifica-
tion 400×).
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We have recently observed that the susceptibility of
VSMCs to cytokine-induced activation is significant-
ly reduced after early cell-cycle arrest.24 By dampen-
ing this initial VSMC activation in response to acute
injuries of grafting, inhibition of cell-cycle regulatory
gene expression has allowed grafts to respond to the
more chronic hemodynamic stress of the arterial cir-
culation through medial thickening that does not
involve the expression of proinflammatory genes. The
eventual dissipation of E2F decoy activity allows pro-
liferation of medial VSMCs to contribute to this
process in the absence of acute vascular injuries that
can trigger VSMC activation, migration, and neointi-
ma formation. In the current study vein grafts that had
received a single intraoperative transfection with E2F
decoy ODNs and that initiated an adaptive response
that did not involve neointimal hyperplasia continued
to resist neointima formation and atherosclerosis as
long as 6 months after operation. These results indi-
cate that once hemodynamic stability has been
achieved, the vein graft wall is no longer subject to
stimuli for vascular cell activation and neointimal
hyperplasia, and that long-term resistance to neointi-
mal disease and atherosclerosis may therefore be
observed in a clinical setting.
The cholesterol-fed rabbit offers a model of vein
graft atherosclerosis that produces lesions reminiscent
of those seen in human disease.15 In addition, as in
human vein grafts, the time course of this lesion for-
mation is greatly accelerated compared with native
arterial disease because plaque forms in hypercholes-
terolemic rabbit grafts over the course of weeks in con-
trast to the months required for atherosclerosis in the
rabbit aorta.15,25 This experimental atherogenesis, how-
ever, begins during the early postoperative period in the
context of active vascular cell stimulation and prolifer-
ative activity at levels higher than those present during
the course of human graft atherosclerotic lesion devel-
opment. We therefore examined whether this increased
susceptibility to atherogenesis was sustained as a
chronic characteristic of the graft neointima and
whether reduction of the neointimal component of vein
graft adaptation could therefore be expected to influ-
ence the grafts’ long-term likelihood of disease. Rabbit
vein grafts were found to develop atherosclerotic
lesions on exposure to hypercholesterolemia, even after
a 6-month period of stabilization in the arterial circula-
tion. More important, the avoidance of neointima for-
mation and the alternative adaptation undertaken by
grafts that had been treated once with E2F decoy ODNs
at the time of operation 6 months earlier prevented
lesion formation, even after a delayed exposure to a
proatherogenic environment.
In summary, we have demonstrated that the long-
term biology of the vessel wall is dramatically influ-
enced by the events of the vein graft harvest and
implantation into the arterial circulation and that a
long-term protective shift from a pathologic phenotype
can be achieved by a strategy of transient but critical
alteration of specific vascular cell genetic activity
around the time of operation. Vein graft disease offers
a somewhat unique opportunity for translation of a
molecular therapeutic strategy to human application.
Unlike native arterial atherosclerosis, vein graft dis-
ease is known to begin at a discrete point in time, a
time at which the tissue is readily accessible to direct
intervention and therefore to possible manipulation of
the genetic machinery driving pathogenesis. In addi-
tion, vein graft disease results from exposure of rela-
tively normal tissue to an abnormal physiologic envi-
ronment and is therefore more amenable to accurate
experimental modeling than the more complex and
multifactorial human atherosclerosis in native arteries.
Furthermore, the ex vivo availability of the vein grafts
allows easier application in the human clinical setting
of DNA transfer techniques, such as pressure-mediat-
ed delivery, that provide highly efficient, targeted, and
safe genetic manipulation. The observations reported
in this study, coupled with freedom from viral and
other potentially hazardous DNA transfer methodolo-
gies, have provided a foundation for the initiation of
clinical studies of this gene-based approach for the
amelioration of human vein graft disease.26 Future
large-scale studies may provide further insight into the
feasibility of intraoperative manipulation of the genet-
ic roots of a common human cardiovascular disease.
Received for publication March 15, 2000; revisions
requested June 26, 2000; revisions received Aug 23, 2000;
accepted for publication Aug 31, 2000.
Address for reprints: Victor J. Dzau, MD, Tower 1, Office
of the Chairman, Department of Medicine, Brigham and
Women’s Hospital/Harvard Medical School, 75 Francis St,
Boston, MA 02115 (E-mail: vdzau@rics.bwh.harvard.edu).
R E F E R E N C E S
1. Campeau L, Enjalbert M, Lesperance J, Bourassa MG,
Kwiterovich P Jr, Wacholder S, et al. The relation of risk factors
to the development of atherosclerosis in saphenous vein bypass
grafts and the progression of disease in the native circulation: a
study 10 years after aortocoronary bypass surgery. N Engl J Med
1984;311:1329-34.
2. Grondin CM. Late results of coronary artery grafting: is there a
flag on the field? J Thorac Cardiovasc Surg 1984;87:161-6.
3. Reardon MJ, Conklin LD, Reardon PR, Baldwin JC. Coronary
artery bypass conduits: review of current status. J Cardiovasc
Surg 1997;97:916-31.
722 Ehsan et al The Journal of Thoracic and
Cardiovascular Surgery
April 2001
4. Clowes AW, Reidy MA. Prevention of stenosis after vascular
reconstruction: pharmacologic control of intimal hyperplasia. J
Vasc Surg 1991;13:885-90.
5. Fulton GJ, Davies MG, Koch WJ, Dalen H, Svendsen E, Hagan
P-O. Antisense oligonucleotide to proto-oncogene c-myb inhibits
the formation of intimal hyperplasia in experimental vein grafts.
J Vasc Surg 1997;24:453-63.
6. Bai H, Morishita R, Kida I, Yamakawa T, Zhang W, Aoki M, et al.
Inhibition of intimal hyperplasia after vein grafting by in vivo
transfer of human senescent cell-derived inhibitor-1 gene. Gene
Ther 1998;5:761-9.
7. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP,
et al. Genetic engineering of vein grafts resistant to atherosclero-
sis. Proc Natl Acad Sci USA 1995;92:4502-6.
8. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR.
The E2F transcription factor is a cellular target for the RB pro-
tein. Cell 1991;65:1053-61.
9. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation
by the E2F1 transcription factor include DNA synthesis- and
G1/S-regulatory genes. Mol Cell Biol 1995;15:4215-24.
10. Weinberg RA. The retinablastoma protein and cell cycle control.
Cell 1995;81:323-30.
11. Nevins JR. Towards an understanding of the functional complex-
ity of the E2F and retinoblastoma families. Cell Growth Differ
1998;9:585-93.
12. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama
M, Zhang L, et al. A gene therapy strategy using a transcrip-
tion factor decoy of the E2F binding site inhibits smooth
muscle proliferation in vivo. Proc Natl Acad Sci USA
1995;92:5855-9.
13. Mann MJ, Gibbons GH, Hutchinson H, Poston RS, Hoyt EG,
Robbins RC, et al. Pressure-mediated oligonucleotide transfec-
tion of rat and human cardiovascular tissues. Proc Natl Acad Sci
USA 1999;96:6411-6.
14. Batellier J, Wassef M, Merval R, Duriez M, Tedgui A. Protection
from atherosclerosis in vein grafts by a rigid external support.
Arterioscler Thromb 1993;13:379-84.
15. Zwolak RM, Kirkman TR, Clowes AW. Atherosclerosis in rabbit
vein grafts. Arteriosclerosis 1989;9:374-9.
16. George SJ, Baker AH, Angelini GD, Newby AC. Gene transfer of
tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase
activity and neointima formation in human saphenous veins.
Gene Ther 1998;5:1552-60.
17. Schwartz LB, Moawad J, Svensson EC, Tufts RL, Meyerson SL,
Baunoch D, et al. Adenoviral-mediated gene transfer of a consti-
tutively active form of the retinoblastoma gene product attenuates
neointimal thickening in experimental vein grafts. J Vasc Surg
1999;29:874-81.
18. Cox JL, Chaisson DA, Gotleib AI. Stranger in a strange land: the
pathogeneis of saphenous vein graft stenosis. Prog Cardiovasc
Dis 1991;34:45-68.
19. Kohler TR, Kirkman TR, Gordon D, Clowes AW. Mechanism of
long-term degeneration of arterialized vein grafts. Am J Surg
1990;160:257-61.
20. Loppnow H, Libby P. Proliferating or interleukin 1-activated
human vascular smooth muscle cells secrete copious interleukin
6. J Clin Invest 1990;85:731-8.
21. Majesky MW, Giachelli CM, Reidy MA, Schwartz SM. Rat
carotid neointimal smooth muscle cells reexpress a developmen-
tally regulated mRNA phenotype during repair of arterial injury.
Circ Res 1992;71:759-68.
22. Heagerty AM. Changes in vascular morphology in essential
hypertension. J Hum Hypertens 1991;5(Suppl 1):3-8.
23. Koffi I, Safer ME, Labat C, Lacolley P, Benetos A, Mourad JJ.
Arterial structural changes with verapamil in spontaneously
hypertensive rats. Am J Hypertens 1999;12:732-8.
24. Braun-Dullaeus RC, Mann MJ, von der Leyen HE, Dzau VJ. Cell
cycle dependent modulation of VCAM-1 expression in vascular
smooth muscle cells is transcriptionally regulated through IRF-1
[abstract]. Circulation 1998;98(Suppl):I-601.
25. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham
ME. Antiatherogenic effects of L-arginine in the hypercholes-
terolemic rabbit. J Clin Invest 1992;90:1168-72.
26. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte
MS, Polak JF, et al. Ex-vivo gene therapy of human vascular
bypass grafts with E2F decoy: the PREVENT single-centre,
randomised, controlled trial. Lancet 1999;354:1493-8.
